Key result
Ginsenoside Rb1 treatment significantly improved left ventricular ejection fraction (71.3% vs 67.6%, p<0.001) and attenuated cardiac inflammation and fibrosis in rats with diabetic cardiomyopathy.
Why the study?
Ginsenosides play an important role in the treatment of diabetes and obesity, leading to the hypothesis that ginsenoside Rb1 combined with insulin would have a protective effect in diabetic cardiomyopathy.
Does ginsenoside Rb1 improve cardiac function and attenuate myocardial injury in a rat model of diabetic cardiomyopathy?
Population
8 w old male Sprague-Dawley rats with induced diabetic cardiomyopathy
Comparison
Ginsenoside Rb1 at different doses vs controls
Design
Randomized preclinical animal study
Follow-up
6 w
Authors
Loading...
Hypothesis-generating for ginsenoside Rb1 in diabetic cardiomyopathy; human trials needed before clinical consideration.
Does ginsenoside Rb1 improve cardiac function and attenuate myocardial injury in a rat model of diabetic cardiomyopathy?
Absolute Event Rate: 71.3% vs 67.6%
p-value: p=<0.001
Ginsenoside Rb1 attenuates cardiac inflammation and fibrosis and improves cardiac function in a rat model of diabetic cardiomyopathy by inhibiting the HB-EGF pathway.
Zhang et al. (2022) studied Diabetic Cardiomyopathy (n=40). Ginsenoside Rb1 vs. Insulin only or normal saline was evaluated on Left Ventricular Ejection Fraction (LVEF) (p=<0.001). Ginsenoside Rb1 treatment significantly improved left ventricular ejection fraction (71.3% vs 67.6%, p<0.001) and attenuated cardiac inflammation and fibrosis in rats with diabetic cardiomyopathy.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: